BioCentury
ARTICLE | Company News

Aveo Pharmaceuticals, Canbridge deal

March 28, 2016 7:00 AM UTC

Aveo granted Canbridge exclusive, ex-North American rights to oncology candidate AV-203. Aveo will receive $1 million up front and is eligible for $133 million in milestones, plus tiered, low double-digit royalties. Canbridge said it plans to develop the erb-b2 receptor tyrosine kinase 3 ( ERBB3; HER3; EGFR3)-targeted antibody to treat esophageal squamous cell cancer (ESCC). ...